Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors

J Dermatol. 2020 Apr;47(4):e126-e127. doi: 10.1111/1346-8138.15198. Epub 2019 Dec 23.

Authors

Affiliations

¹ Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
² Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
³ Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.

PMID: 31872454
DOI: 10.1111/1346-8138.15198

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Asymptomatic Diseases / therapy
Biopsy, Fine-Needle
Female
Humans
Imidazoles / pharmacology
Imidazoles / therapeutic use
Liver Neoplasms / diagnosis
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Melanoma / diagnosis
Melanoma / drug therapy*
Melanoma / secondary
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
Oximes / pharmacology
Oximes / therapeutic use
Pancreas / diagnostic imaging
Pancreas / pathology
Pancreatic Neoplasms / diagnosis
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / pathology
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Pyridones / pharmacology
Pyridones / therapeutic use
Pyrimidinones / pharmacology
Pyrimidinones / therapeutic use
Tomography, X-Ray Computed
Treatment Outcome
Ultrasonography

Substances

Imidazoles
Oximes
Protein Kinase Inhibitors
Pyridones
Pyrimidinones
trametinib
BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases
dabrafenib